Topical antiviral formulations
AssigneesThe CONRAD Program of the Eastern Virginia Medical School (“CONRAD”), International Partnership for Microbicides, Inc.
InventorTerrence C. Dahl
Life of this patent
Estimating the term…
Abstract
The present invention relates to formulations of nucleotide reverse transcriptase inhibitors (NRTIs), preferably [2-(6-Amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid (tenofovir, PMPA), or a physiologically functional derivative thereof, suitable for topical application and their use in the prevention of HIV infections.
Claims1
A method for prophylactically reducing a risk of HIV transmission and/or infection during sexual activity between two animals, wherein at least the first animal is infected with HIV, which comprises administering to the second animal an effective amount of a topical formulation comprising an effective amount of a nucleotide reverse transcriptase inhibitor (NRTI) in combination with a pharmaceutically acceptable vehicle, wherein the NRTI further comprises [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid (tenofovir) or a physiologically functional derivative thereof, and the topical formulation further comprises a vaginal gel formulation comprising:
- [2-(6-amino-purin-9-yl)-1-methyl-
- 1.00
- (% w/w)
- ethoxymethyl]-phosphonic acid
- Hydroxyethylcellulose
- 2.50
- Propylparaben
- 0.02
- methylparaben
- 0.18
- edetate disodium
- 0.05
- glycerin
- 20.00
- citric acid
- 1.00
- purified water
- 75.25.
Dependencies are inferred from the claim text.